Name of Journal: *World Journal of Cardiology*

Manuscript NO: 52181

Manuscript Type: CASE REPORT

Subclavian Impella 5.0 to the rescue in a non-ST elevation myocardial infarction patient requiring unprotected left main rotablation: A case report

Vasileios Panoulas, María Monteagudo-Vela, Konstantinos Kalogeras, Andre Simon

Abstract

BACKGROUND

Often in patients with significant three-vessel or left main disease there is

检测到您输入了英文，试试切换到国际版？搜英文结果更丰富更准确

11,300 条结果 时间不限

The Impella 5.0: A Brief Overview | Cath Lab Digest 翻译此页

Background Rationale Introduction Description Indicat

Cardiogenic shock is associated with a mortality of 35% to 80%.1,2 Lately, there has been a shift in reliance upon aggressive pharmacological therapy alone to a more hybrid approach, incorporating innovative mechanical therapy to conventional pharmacological management. It is well established that pharmacological support with inotropic agents in cardiogenic shock results in an increasing oxygen demand from myocardial tissue, as w…

在cathlabdigest.com上查看更多信息

发布日期: 2014-9-2

https://www.cathlabdigest.com/article/**Impella-50**-Brief-Overview

Mechanical circulatory support in cardiogenic shock ... 翻译此页

Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO ... the Impella 2.5 or Impella CP. Mean patient age was 66 ± 12.5 years, 76% were ...

https://www.researchgate.net/publication/334747593_Mechanical_circulatory_support_in...

High Risk Coronary Atherectomy, Perforation, and ... 翻译此页

We report a case of coronary perforation during high-risk percutaneous coronary intervention with Impella

461 Results Any time

Ventricular Assist Devices - Medical Clinical Policy ...

www.aetna.com/cpb/medical/data/600_699/0654.html

Policy Background Appendix

Aetna considers a Food and Drug Administration (FDA)-approved ventricular assist device (VAD) medically necessary for any of the following FDA-approved indications: 1. As a bridge to transplant for members who are awaiting heart transplantation (see CPB 0586 - Heart Transplantation) and the device has received FDA approval for a bridge to transplant indication (e.g., HeartMate 3 left ventricular assist system (LVAS)); or 2. As destination therapy when all of the following criteria are met: 1....

See more on aetna.com

2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus ...

www.onlinejacc.org/content/65/19/e7

May 19, 2015 · **Patient**-specific variables include increased age, impaired **left** ventricular function, symptoms of heart failure, diabetes mellitus, chronic kidney disease, prior **myocardial infarction**, multivessel or **left main** disease, and peripheral arterial disease .

Cited by: 361 **Author:** Charanjit S. Rihal, Srihari S. Naidu, Mich…

Publish Year: 2015